Michael Secora - Feb 1, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Financial Officer
Signature
/s/ Nathan Hatfield, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Feb 1, 2023
Transactions value $
-$22,820
Form type
4
Date filed
2/3/2023, 04:14 PM
Previous filing
Nov 17, 2022
Next filing
Feb 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +202K +34.42% $0.00 791K Feb 1, 2023 Direct F1, F2
transaction RXRX Class A Common Stock Award $0 +7.74K +0.98% $0.00 798K Feb 1, 2023 Direct F3
transaction RXRX Class A Common Stock Tax liability -$22.8K -2.67K -0.33% $8.55 796K Feb 1, 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Award $0 +405K $0.00 405K Feb 1, 2023 Class A Common Stock 405K $8.55 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2023 and every three months thereafter.
F2 Includes 1,502 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2022.
F3 This RSU vested immediately upon the grant date.
F4 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F5 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.